Sanofi’s Dupixent Benefits In Chronic Spontaneous Urticaria Add To Strong Second Quarter
EPS Guidance For 2021 Updated
Executive Summary
Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.
You may also be interested in...
Sanofi Hits Rare Setback For Dupixent In Urticaria
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.
Sanofi Goes All The Way In mRNA With Translate Bio Buy
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.